11/28/2022 0 Comments Magna graecia ii![]() So, SC TCZ was given on 3 April 2020, with no adverse events recorded. Plasma concentration of IL‐6 was 72.65 pg/mL after 3 days from admission, with worsening of symptoms and persistence of fever. The day after admission, nasal flow oxygen therapy was prescribed (2 L/min), followed by Venturi mask (at 15 L/min, FiO 2 = 60%) for worsening of SpO 2 from 98% to 94%. Antiviral treatment with hydroxychloroquine and azithromycin was started. She was admitted on 29th March with fever, cough, tachypnoea, and occasional shortness of breath. The second patient was a 57‐year‐old woman who suffered from hypertension, diabetes, obesity, and depression. Panel A and B for each patients show evolution of lung disease at high‐resolution computerized tomography before and after subcutaneously tocilizumab Significant reduction of IL‐6 was observed in 1 week (from 106.1 to 6.32 pg/mL) with a clear improvement of radiological findings at high‐resolution computerized tomography from 1st April to 18th April 2020 (see Figure 1A,B, respectively). Fever disappeared 2 days after and oxygen support was progressively decreased and stopped 12 days after TCZ administration. No major adverse events were reported apart from mild increase of liver function tests 2 days following SC TCZ (ALT 201 UI/L AST 108 UI/L), with subsequent rapid normalization. For persistence of dyspnoea and on the basis of radiologic findings and IL‐6 serum level (106.1 pg/mL), SC TCZ was administered on 1 April 2020. An antibiotic coverage for pneumonia with piperacillin/tazobactam was added. Oxygen was administered with high flow nasal cannula at 60 L/min with FiO 2 = 75%. She was already on treatment with azithromycin, lopinavir/ritonavir, and hydroxychloroquine from 28 March 2020. She was admitted to our hospital on 31 March 2020, with cough, fever, and shortness of breath. The first patient was a 61‐year‐old woman who had only hypercholesterolemia in her past medical history. Treatment course for these patients is described below. We have treated three patients with this drug at a single dose of 162 mg given subcutaneously, in line with data showing similar efficacy compared to intravenously given TCZ for different diseases. However, to the best of our knowledge data on subcutaneous (SC) use of TCZ are lacking. This adds to several data emerging from case reports and uncontrolled studies. Described their experience with intravenous tocilizumab (TCZ) in treating severe coronavirus disease 2019 (COVID‐19). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |